H
Health Catalyst Inc (HCAT)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
$1.38
-0.13 (-8.61%)
Market Cap: $115.00M
Last updated: Nov 17, 2026 at 11:05 AM ET
Health Catalyst Inc (HCAT) Valuation Multiples
Health Catalyst (HCAT) trades at 0.4x sales and 0.7x book value. Its P/S of 0.4x is below its 5-year median of 1.4x. Its forward P/E is 10.0x.
Current Multiples
Its free cash flow yield is 24.7%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 10.0x |
| Price to sales | 0.4x |
| Price to book | 0.7x |
| Price to FCF | 4.0x |
| EV/FCF | 2.0x |
| PEG | N/A |
| FCF yield | 24.7% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 0.4x | 1.4x | N/A |
| P/B | 0.7x | 1.2x | N/A |
Valuation History
Over the 3 of the 7 year ends shown that have a P/E, its P/E ranged from 25.3x in 2024 to 61.7x in 2023.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $2.39 | 34.1x | 0.5x | 0.7x |
| 2024 | $7.07 | 25.3x | 1.4x | 1.2x |
| 2023 | $9.26 | 61.7x | 1.8x | 1.5x |
| 2022 | $10.63 | N/A | 2.1x | 1.4x |
| 2021 | $39.62 | N/A | 7.8x | 4.0x |
| 2020 | $43.53 | N/A | 9.1x | 6.7x |
| 2019 | $34.70 | N/A | 1.9x | 6.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HCAT
What is HCAT's forward P/E ratio?
Health Catalyst has a forward P/E ratio of 10.0x.
Is HCAT stock overvalued?
GNG's valuation label for HCAT is Undervalued.
What is HCAT's price to sales ratio?
Health Catalyst has a price to sales ratio of 0.4x.
HCAT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors